Louise Chen
Stock Analyst at Scotiabank
(3.20)
# 2,825
Out of 4,862 analysts
301
Total ratings
44.57%
Success rate
1.33%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $36.18 | +121.12% | 3 | Jun 6, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Sector Perform | $135 | $127.96 | +5.50% | 2 | Jun 2, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $1.47 | +512.24% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $15.29 | -8.44% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.73 | +593.64% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $21.67 | +153.81% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $51.25 | +7.32% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $3.17 | +373.19% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $25.89 | +93.12% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $3.60 | +316.67% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $7.09 | +139.77% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $31.33 | +123.43% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $14.40 | +247.22% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $15.39 | +94.93% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $41.00 | +34.15% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.83 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $79.83 | +100.43% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $34.56 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $24.54 | +83.37% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $157.10 | +36.86% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.13 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $81.71 | +89.70% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.33 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $819.36 | +8.01% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.93 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.66 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.78 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.34 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $22.84 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $191.08 | +4.67% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.83 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.63 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.25 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.75 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $529.24 | +74.78% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.81 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $2.93 | +2,118.43% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.95 | +426.32% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $2.49 | +904.02% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $16.90 | +195.86% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.43 | +272.30% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.19 | +320.17% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.90 | +900.67% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $3.49 | +48,352,335.53% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $419.90 | -38.56% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $16.99 | -11.71% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.93 | +2,490.67% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.33 | +1,403.76% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $6.78 | +563.72% | 1 | Jun 22, 2017 |
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $36.18
Upside: +121.12%
Blueprint Medicines
Jun 2, 2025
Downgrades: Sector Perform
Price Target: $135
Current: $127.96
Upside: +5.50%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $1.47
Upside: +512.24%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $15.29
Upside: -8.44%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.73
Upside: +593.64%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $21.67
Upside: +153.81%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $51.25
Upside: +7.32%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.17
Upside: +373.19%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $25.89
Upside: +93.12%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.60
Upside: +316.67%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $7.09
Upside: +139.77%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $31.33
Upside: +123.43%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $14.40
Upside: +247.22%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $15.39
Upside: +94.93%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $41.00
Upside: +34.15%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.83
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $79.83
Upside: +100.43%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $34.56
Upside: -
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $24.54
Upside: +83.37%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $157.10
Upside: +36.86%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.13
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $81.71
Upside: +89.70%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.33
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $819.36
Upside: +8.01%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.93
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.66
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.78
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.34
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.84
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $191.08
Upside: +4.67%
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.83
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.63
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.25
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.75
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $529.24
Upside: +74.78%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.81
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $2.93
Upside: +2,118.43%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $0.95
Upside: +426.32%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $2.49
Upside: +904.02%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $16.90
Upside: +195.86%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.43
Upside: +272.30%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.19
Upside: +320.17%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.90
Upside: +900.67%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $3.49
Upside: +48,352,335.53%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $419.90
Upside: -38.56%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $16.99
Upside: -11.71%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.93
Upside: +2,490.67%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.33
Upside: +1,403.76%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $6.78
Upside: +563.72%